<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1-5828-23
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2022
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        VASCEPA 1GM CAPSULE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ICOSAPENT ETHYL
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        g
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Capsule, soft
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        120
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        668.05
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Patheon Soft Gels BV" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Patheon Soft Gels BV
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 530]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Salehiya Trading Co.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Amarin Pharmaceuticals Ireland Ltd
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C10AX06
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Vascepa contains the active substance icosapent ethyl, a single highly purified omega-3 fatty acid from fish oil that <strong>lowers certain types of fat and related lipids in the blood.</strong></p><p>Vascepa is used in adults who have high blood fats (triglycerides):</p><p>&bull; Who are at high risk of cardiovascular events due to heart disease or diabetes and at least one other risk factor for heart disease. Vascepa is used along with statins (medicines to lower cholesterol) to reduce the risk of cardiovascular events, such as:</p><p>&bull; death from heart disease</p><p>&bull; heart attacks</p><p>&bull; stroke</p><p>&bull; chest pain requiring hospitalisation</p><p>&bull; certain types of heart issues requiring surgery to restore blood flow to the heart due to a build-up of fatty deposits in your arteries.</p><p>&bull; along with a low-fat and low-cholesterol diet to lower high levels of triglycerides (fats).</p><p>It is used in adults aged 18 years and older.</p><p>It is not known if VASCEPA changes your risk of having inflammation of your pancreas (pancreatitis)</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Vascepa:</strong><br />&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are <strong>allergic to icosapent ethyl</strong> or any of the other ingredients of this medicine (listed in section 6).</p><p>&nbsp;</p><p><strong>Take special care with Vascepa if you:</strong><br />&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have diabetes.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have a low thyroid problem (hypothyroidism)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have a liver problem. Your doctor should do blood tests during treatment.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have a pancreas problem.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are allergic to fish and/or shellfish.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have problems with irregular heartbeat (atrial fibrillation or flutter).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are at risk of bleeding due to taking blood thinner medicines (anticoagulants).</p><p>&nbsp;</p><p>You should talk to your doctor about being placed on an appropriate fat-lowering diet and exercise plan.&nbsp; You should continue this plan while on Vascepa.</p><p>&nbsp;</p><p><u>Blood tests</u></p><p>During your treatment your doctor may carry out blood tests to ensure there are no problems with your liver, and also to see how your blood is clotting.</p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p>Do not give this medicine to children and adolescents below 18&nbsp;years of age because it has not been studied in these populations.</p><p>&nbsp;</p><p><strong>Other medicines and Vascepa</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. If you are taking other medicines at the same time as Vascepa that affect how your blood clots such as blood thinners (anticoagulants), your blood will be monitored during treatment.</p><p>&nbsp;</p><p><strong>Pregnancy, breastfeeding </strong><strong>and fertility</strong></p><p>If you are pregnant or breastfeeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p><strong>&nbsp;</strong></p><p><u>Pregnancy</u></p><p>It is not recommended for use during pregnancy unless advised by your doctor.</p><p>&nbsp;</p><p><u>Breastfeeding</u></p><p>It is not recommended for use while breastfeeding as the effect on your newborn baby is not known. Your doctor will help weigh the risks and benefits of the treatment if you are breastfeeding.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>Talk with your doctor about fertility during treatment.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>This medicine is unlikely to affect your ability to drive or use any tools or machines.</p><p>&nbsp;</p><p><strong>Vascepa contains maltitol and sorbitol</strong></p><p><u>Maltitol</u></p><p>If you have been told by your doctor that you have an intolerance to some sugars, talk to your doctor before taking this medicine.</p><p><u>Sorbitol</u></p><p>This medicine contains up to 83&nbsp;mg sorbitol in each capsule.<br />Sorbitol is a source of fructose. If your doctor has told you that you have an intolerance to some sugars or if you have been diagnosed with hereditary fructose intolerance (HFI), a rare genetic disorder in which a person cannot break down fructose, talk to your doctor before you take or receive this medicine.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure. Do not change your dose without talking to your doctor.</p><p>&nbsp;</p><p><u>How much to take</u></p><p>The recommended dose is two capsules by mouth, twice a day, with or following a meal.</p><p>Swallow the capsules whole; <strong>Do not</strong> break, crush, dissolve or chew the capsules.</p><p>&nbsp;</p><p><strong>Use in elderly</strong></p><p>There is no need to change the dose in elderly patients. They can take the usual recommended dose.</p><p>&nbsp;</p><p><strong>If you take more Vascepa than you should</strong></p><p>If you accidentally take more capsules than your doctor prescribed, contact your doctor or pharmacist for advice.</p><p>&nbsp;</p><p><strong>If you forget to take Vascepa</strong></p><p>If you miss a dose, take it as soon as you remember. However if you miss one day of this medicine, <strong>do not take a double dose</strong> to make up for a forgotten dose. If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p><p>&nbsp;</p><p><strong>If you stop taking Vascepa</strong></p><p>Do not stop taking this medicine until you have spoken with your doctor.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong>Contact your doctor</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you experience heart palpitations or irregular heartbeat. These symptoms could be due to a serious condition known as atrial fibrillation.<strong> </strong>This is a<strong> common</strong> side effect (may affect up to 1&nbsp;in&nbsp;10&nbsp;people).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you bruise easily or cannot stop bleeding. This is a <strong>very common</strong> side effect (may affect more than 1&nbsp;in&nbsp;10&nbsp;people). Your risk of bleeding may increase if you are also taking a blood thinner medicine.</p><p>&nbsp;</p><p><strong>Seek medical attention</strong> if you get any of the following side effects. These symptoms could be due to a serious condition known as <strong>hypersensitivity</strong> which can happen at any time during treatment. This is an <strong>uncommon</strong> side effect (may affect up to 1&nbsp;in&nbsp;100&nbsp;people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty breathing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tightening or scratching of the throat</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling of the lips</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hives (raised bumps on the skin)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rash and an itchy skin</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stomach pain or cramps</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nausea and vomiting</p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p><u>Other side effects that may occur</u></p><p><strong>&nbsp;</strong></p><p><strong>Common</strong> side effects (may affect up to 1&nbsp;in&nbsp;10&nbsp;people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling of your hands, arms, legs and feet</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle and joint pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; gout</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rash</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; constipation</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; burping</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; throat pain</p><p>&nbsp;</p><p><strong>Uncommon</strong> side effect (may affect up to 1&nbsp;in&nbsp;100&nbsp;people)</p><ul><li>bad taste in the mouth</li></ul><p><strong>&nbsp;</strong></p><p>If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Keep this medicine </strong><strong>out of the sight and reach of children.</strong></p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the package after EXP.&nbsp; The expiry date refers to the last day of that month.</p><p>Do not store above 30<sup>o</sup>C.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The <strong>active substance</strong> is icosapent ethyl. Each Vascepa capsule contains 1&nbsp;gram of icosapent ethyl.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are</p><p>o&nbsp;&nbsp; all-rac-alpha-Tocopherol, Gelatin, Glycerol, Maltitol (E965&nbsp;ii), Sorbitol (E420&nbsp;ii) (see section 2 &ldquo;Vascepa contains maltitol and sorbitol&rdquo;), Purified water and Lecithin.</p><p>o&nbsp;&nbsp; printing ink: Titanium dioxide, Propylene glycol, Hypromellose.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                	Supplied as 1-gram, amber-colored, soft-gelatin capsules imprinted with ‘VASCEPA’.  One bottle containing 120 capsules.
	

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Amarin Pharmaceuticals Ireland Ltd.</p><p>Care Of (C/O) Amarin Pharma, Inc.</p><p>440 Route 22, Bridgewater,</p><p>NJ 08807, USA</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                June 2023
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي فاسيبا على المادة الفعالة إيكوسبنت إيثيل، وهي حمض دهني أوميغا 3 بدرجة عالية من النقاء أحادي مستخرج من زيت السمك ويعمل على خفض أنواع معينة من الدهون والشحوم المرتبطة بها في الدم.</p><p>ويستخدم فاسيبا للمرضى البالغين الذين يعانون من ارتفاع نسبة الدهون في الدم&nbsp; (الدهون الثلاثية):</p><p>- المرضى المعرضون بشدة لخطر الإصابة بأمراض القلب والأوعية الدموية الناتجة عن أمراض القلب أو مرض السكري مع عامل خطر إضافي واحد على الأقل قد يؤدي للإصابة بأمراض القلب.</p><p>&nbsp;يُستخدم فاسيبا إلى جانب الستاتينات (أدوية خفض نسبة الكوليسترول ) لتقليل خطر بالاصابة بأمراض القلب والأوعية الدموية، مثل:</p><p>- الوفاة بسبب أمراض القلب.</p><p>- الأزمات القلبية.</p><p>- السكتات الدماغية.</p><p>- الام الصدر التي تتطلب دخول المستشفى.</p><p>- أنواع معينة من مشاكل القلب التي تحتاج إلى تدخل جراحي لاستعادة تدفق الدم إلى القلب بسبب تراكم الرواسب الدهنية في الشرايين</p><p>- مع نظام غذائي منخفض الدهون والكوليسترول- لخفض المستويات المرتفعة من الدهون الثلاثية.</p><p>&nbsp;و أكثريُستخدم للبالغين من عمر ١٨ عامًا</p><p>من غير المعروف ما إذا كان فاسيبا يغير من احتمالية وجود خطر إصابتك بالتهاب البنكرياس</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>) موانع الإستعمال</strong></p><p dir="RTL">- تعاني من حساسية ضد الإيكوسبنت ايثيل ، أو أيٍّ من مكونات الدواء الأخرى المُدرجة في القسم رقم ٦.</p><p dir="RTL"><strong>ب) الإحتياطات عند استعمال فاسيبا:</strong></p><p dir="RTL">- إن كنت مريض بداء السكري<br />- إن كنت تعاني من قصور الغدة الدرقية.<br />- إن كان لديك مشكلة في الكبد. ينبغي على طبيبك أن يجري اختبارات الدم أثناء العلاج.<br />- إن كان لديك مشكلة في البنكرياس.</p><p dir="RTL">&nbsp;-إن كنت تعاني من حساسية من الأسماك والمحار.</p><p dir="RTL">- إن كنت تعاني من مشكلات ناجمة عن عدم انتظام ضربات القلب (الرجفان الأذيني أو الرفرفة الأذنية).</p><p dir="RTL">- إن كنت معرضاً لخطر النزف بسبب تناول أدوية مضادة لتجلط الدم (مضادات التخثر).<br />&nbsp;ينبغي عليك أن تتحدث مع طبيبك بشأن اتّباع حمية غذائية مناسبة لخفض الدهون وخطة للتمارين الرياضية، ويجب عليك متابعة هذه الخطة أثناء فترة تناولك دواء فاسيبا.</p><p><strong>اختبارات الدم</strong></p><p dir="RTL">قد يقوم طبيبك خلال فترة العلاج بإجراء اختبارات للدم؛ وذلك للتحقق من عدم وجود مشكلات في الكبد، وكذلك لمعرفة كيفية تخثر الدم.</p><p dir="RTL">&nbsp;</p><p><strong>الأطفال والمراهقون</strong></p><p>لا يجوز إعطاء هذا الدواء للأطفال والمراهقين الذين تقل أعمارهم عن&nbsp; ١٨ عامًا لأن تأثيره على هذه الفئة العمرية لم يتم دراسته بعد.</p><p>&nbsp;</p><p><strong>ج) التدخلات الدوائية عند أخذ فاسيبا مع أي أدوية أخرى أو أعشاب أو مكملات غذائية</strong></p><p>أخبر الطبيب أو الصيدلي إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أي أدوية أخرى.</p><p dir="RTL">إذا كنت تتناول أدويةً أخرى قد تؤثر على تخثر الدم أثناء تناولك فاسيبا مثل أدوية سيولة الدم &nbsp;(مضادات التخثر) فسيتم فحص دمك بصورة مستمرة خلال فترة العلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ه)الحمل والرضاعة </strong><strong>والخصوبة</strong></p><p dir="RTL">إذا كُنتِ حاملًا، أو ترضعين طفلك رضاعةً طبيعية، أو تعتقدين أنك حامل أو تخططين للحمل، فاستشيري طبيبكِ أو الصيدلي قبل تناول هذا الدواء.</p><p dir="RTL"><strong><u>الحمل</u></strong></p><p dir="RTL">من غير المستحسن أن يُستخدم فاسيبا خلال فترة الحمل ما لم يصفه لك الطبيب.</p><p dir="RTL"><strong><u>الرضاعة</u></strong></p><p>من غير المستحسن أن يُستخدم فاسيبا خلال فترة الرضاعة الطبيعية حيث لا يزال تأثيره على الأطفال حديثي الولادة غير معروف. إذا كنت ترضعين طفلك رضاعة طبيعية؛ سيساعدك طبيبكِ على الموازنة بين مخاطر وفوائد العلاج.</p><p><strong><u>الخصوبة</u></strong></p><p>تحدث مع طبيبك حول الخصوبة أثناء العلاج.</p><p>&nbsp;</p><p dir="RTL"><strong>و- تأثير فاسيبا على القيادة واستخدام الآلات</strong>.</p><p dir="RTL">من غير المتوقع أن يؤثر هذا الدواء على قدرتك على القيادة أو استخدام أي&nbsp; أدوات أو آلات</p><p dir="RTL">&nbsp;</p><p><strong>فاسيبا يحتوي على المالتيتول والسوربيتول</strong></p><p><strong>المالتيتول</strong></p><p>إذا أخبرك طبيبك أنك لا تحتمل بعض أنواع السكريات، فتحدث إليه قبل أن تتناول هذا الدواء</p><p>&nbsp;</p><p><strong>السوربيتول</strong></p><p>يحتوي الدواء على كمية تصل إلى ٨٣ ملغ من السوربيتول في كل كبسولة والسوربيتول هو مصدر للفركتوز. إذا أخبرك طبيبك أنك تعاني من عدم تحمل بعض أنواع السكريات، أو إذا تم تشخيص إصابتك بعدم التحمل الوراثي للفركتوز -وهو اضطراب وراثي نادر لا يستطيع الشخص المصاب به تكسير الفركتوز- فعليك التحدُّث إلى طبيبك قبل أن تتناول هذا الدواء.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تناول دائمًا هذا الدواء طبقًا لإرشادات الطبيب أو الصيدلي. ويجب مراجعة طبيبك أو الصيدلي إذا لم تكن متأكّدًا. لاتقم بتغيير جرعتك دون استشارة طبيبك.</p><p dir="RTL"><strong><u>الكمية التي يجب تناولها</u></strong></p><p>الجرعة الموصى بها هي كبسولتان يتم تناولهما عن طريق الفم، مرتان في اليوم مع أو بعد تناول الطعام.</p><p>تناول كبسولات فاسيبا كاملة، لا تكسر أو تسحق أو تذيب أو تمضغ الكبسولات</p><p>&nbsp;</p><p><strong>الاستخدام بالنسبة لكبار السن</strong></p><p>لا داعي لتغيير الجرعة بالنسبة للمرضى من كبار السن ويمكنهم تناول الجرعة المعتادة الموصى بها.</p><p dir="RTL"><strong>أ-إذا تناولت فاسيبا أكثر </strong><strong>من اللازم</strong></p><p dir="RTL">إذا تناولت جرعة زائدة عن التي وصفها لك الطبيب عن طريق الخطأ، اتصل بطبيبك أو بالصيدلي لطلب المشورة.إذا كانت لديك أيُّ أسئلة عن استخدام الدواء، فاستشر الطبيب أو الصيدلي.</p><p dir="RTL"><strong>ب-إذا نسيت تناول جرعة فاسيبا</strong><strong> </strong></p><p>إذا فاتتك جرعة من فاسيبا، يمكنك تناولها بمجرد أن تتذكر. ومع ذلك إذا مضى يومٌ كامل دون أن تتناول هذا الدواء، فلا تضاعف جرعتك لتعوض الجرعة المنسية. إذا كانت لديك أي أسئلة بخصوص استخدام الدواء فاستشر الطبيب أو الصيدلي.</p><p><strong>إذا توقفت عن تناول فاسيبا ج-</strong></p><p>لا تتوقف عن تناول هذا الدواء إلا بعد أن تتحدث مع طبيبك</p><p>إذا كانت لديك أي أسئلة إضافية بخصوص استخدام الدواء، فاستشر الطبيب أو الصيدلي</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية يمكن أن يتسبب فاسيبا في ظهور آثار جانبية، على الرغم من عدم ظهورها لدى الجميع.</p><p>اتصل بطبيبك</p><p>- إذا شعرت بخفقان في القلب أو عدم انتظام في ضربات القلب، فقد يكون السبب في هذه الأعراض حالة خطيرة</p><p>تعرف باسم الرجفان الأذيني. وهذه إحدى الآثار الجانبية <strong>الشائعة</strong> (قد تصيب حتى ١ من كل ١٠ أشخاص).</p><p>-إذا &nbsp;كنت تصاب بالكدمات بسهولة أو لا تستطيع إيقاف النزيف، وهذه إحدى الآثار الجانبية <strong>الشائعة جدًّا</strong> (قد تؤثر</p><p>على أكثر من ١ من كل ١٠ أشخاص) وقد يزداد خطر إصابتك بالنزيف إذا كنت تتناول أيضًا دواء مضاد لتخثر الدم</p><p><strong>عليك القيام بطلب الرعاية الطبية </strong>إذا شعرت بأي من الأعراض الجانبية التالية. فقد يكون السبب في هذه الأعراض حالة خطيرة تُعرف باسم <strong>فرط الحساسية</strong> التي يمكن أن تحدث في أي وقت أثناء العلاج</p><p>وهذه إحدى الآثار الجانبية <strong>غير الشائعة</strong> (قد تصيب حتى ١ من كل ١٠٠ شخص)</p><p>صعوبة في التنفس.</p><p>ضيق أو حكة في الحلق.</p><p>تورّم الشفتين.</p><p>شرى )بثور بارزة في الجلد</p><p>طفح جلدي أو حكة في الجلد</p><p>آلام أو تقلصات في المعدة</p><p>إسهال</p><p>قيء وغثيان</p><p><strong><u>أعراض جانبية أخرى قد تحدث</u></strong>:</p><p>أعراض جانبية <strong>شائعة</strong> (قد تصيب حتى ١ من كل ١٠ أشخاص)</p><p>تورّم اليدين والذراعين والساقين والقدمين</p><p>آلام العضلات والمفاصل</p><p>النقرس</p><p>طفح جلدي</p><p>إمساك</p><p>التجشؤ</p><p>آلام الحلق</p><p>أعراض جانبية <strong>غير شائعة</strong> (قد تصيب حتى ١ من كل ١٠٠ شخص)</p><p>طعم سيئ في الفم</p><p dir="RTL">في حال تفاقمت أيٌّ من الآثار الجانبية، أو إذا لاحظت أي عرض جانبي غير وارد في هذه النشرة، يرجى إبلاغ الطبيب أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>يُحفَظ هذا الدواء بعيدًا عن متناول </strong><strong>ومرأى الأطفال</strong></p><p dir="RTL">لا تستخدم الدواء بعد تاريخ انتهاء الصلاحية المذكور على العبوة بعد كلمة EXP. ويشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">يحفظ في درجات حرارة لا تتعدى ٣٠ درجة مئوية .</p><p dir="RTL">لا تتخلّص من الدواء عن طريق مياه الصرف الصحي، أو النفايات المنزلية. واسأل طبيبك عن كيفية التخلُّص من الأدوية التي لا تستخدمها. إن اتّباع هذه التدابير سوف يساعد على حماية البيئة.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعّالة هي إيكوسبنت&nbsp;إيثيل، وتحتوي كل كبسولة على ١ غرام من إيكوسبنت&nbsp;إيثيل.</p><p dir="RTL">المواد غير الفعالة:</p><p>آل-راك-ألفا- توكوفيرول، والجيلاتين، والجليسرول، والمالتيتول -</p><p>راجع القسم ٢ &quot;يحتوي فاسيبا على (المالتيتول والسوربيتول) ( E420 ii)&nbsp; والسوربيتول &nbsp;( E965 ii(</p><p>والمياه النقية والليسيثين</p><p><strong>حبر الطباعة</strong>: الطباعة: ثاني أكسيد التيتانيوم، بروبيلين جلايكول، هايبروميلوز</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يأتي فاسيبا على شكل كبسولات جيلاتينية رخوة (١ غرام)، بلون الكهرمان، مطبوع عليها اسم &quot;فاسيبا&quot;</p><p dir="RTL">تحتوي كل زجاجة على ١٢٠ كبسولة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><strong>مالك رخصة التسويق:</strong></p><p>Amarin Pharmaceuticals Ireland Ltd.</p><p>Care Of (C/O) Amarin Pharma, Inc.</p><p>440 Route 22, Bridgewater,</p><p>NJ 08807, USA</p><p dir="RTL">:<strong>الشركة المُصنعة للشكل الصيدلاني، والمسؤولة عن تحرير الصنف</strong></p><p>Patheon Softgels BV</p><p>De Posthoornstraat 7</p><p>5048 AS Tilburg</p><p dir="RTL">The Netherlands</p><p>للحصول على أي معلومات حول هذا المنتج الطبي، يُرجى الاتصال بالممثل</p><p>المحلي لمالك رخصة التسويق في المملكة العربية السعودية:</p><p>بيولوجيكس، شركة منطقة حرة، شارع هبة الله الغفاري، السليمانية، المملكة</p><p>العربية السعودية ص.ب 991 ، الرياض 11421</p><p>&nbsp;</p><p>+966 11 464 هاتف: 6955</p><p dir="RTL">فاكس: +966 11 463 4362</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            يوليو ٢٠٢٣
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Vascepa 1 gram capsules
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each capsule contains 1 g of icosapent ethyl (containing 2 mg tocopherol as antioxidant).

Excipients with known effect

Each capsule contains up to 30 mg maltitol liquid (E965 ii).

Each capsule contains up to 83 mg sorbitol liquid, non-crystallising (E420 ii).

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Vascepa capsules are supplied as amber-coloured, oblong, soft caspules, 25 mm x 10 mm, imprinted with “VASCEPA”.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Vascepa is an ethyl ester of eicosapentaenoic acid (EPA) indicated:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp; To reduce the risk of cardiovascular events as an adjunct to statin therapy in adult patients with elevated triglycerides (<em>&ge;150 mg/dL)</em>, who are at high risk of cardiovascular events due to:</p><p>o&nbsp;&nbsp; established cardiovascular disease, or</p><p>o&nbsp;&nbsp; diabetes, and at least one other cardiovascular risk factor.</p><p>&nbsp;</p><p>For study details and results with respect to effects on cardiovascular events see section 5.1.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; as an adjunct to diet to reduce TG levels in adult patients with severe (&ge; 500 mg/dL) hypertriglyceridemia.</p><p>&nbsp;</p><p>The effect of Vascepa on the risk of pancreatitis in patients with severe hypertriglyceridemia has not been determined.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>&nbsp;</p><p>Assess lipid levels before initiating therapy. Identify other causes (e.g., diabetes mellitus, hypothyroidism, or medications) of high triglyceride levels and manage as appropriate.</p><p>&nbsp;</p><p>Patients should engage in appropriate nutritional intake and physical activity before receiving Vascepa, which should continue during treatment with Vascepa.</p><p>&nbsp;</p><p>The recommended daily oral dose is 4&nbsp;g taken as two 1&nbsp;g capsules twice daily.</p><p>&nbsp;</p><p>If a dose is missed, patients should take it as soon as they remember. However, if they miss one day of Vascepa, they should not double the dose when they take it.</p><p>&nbsp;</p><p><em>Elderly (&ge;&nbsp;65&nbsp;years)</em></p><p>In well-controlled clinical studies of Vascepa, no overall differences in safety or effectiveness were observed between elderly and younger patients. No dose adjustment is necessary based on age (see section 5.2).</p><p>&nbsp;</p><p><em>Renal impairment </em></p><p>No dose reduction is recommended (see also section 5.2).</p><p>&nbsp;</p><p><em>Hepatic impairment </em></p><p>No dose reduction is recommended (see also sections 4.4 and 5.2).</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>There is no relevant use of icosapent ethyl in children aged &lt;18&nbsp;years of age in reducing the risk of cardiovascular events as an adjunct to statin therapy in patients with elevated triglycerides, who are at high risk of cardiovascular events.</p><p>&nbsp;</p><p><u>Method of administration </u></p><p><u>&nbsp;</u></p><p>Oral use.</p><p>&nbsp;</p><p>Take Vascepa with or following a meal.</p><p>&nbsp;</p><p>To ensure the full intended dose is received, patients should be advised to swallow Vascepa capsules whole. Do not break, crush, dissolve, or chew Vascepa.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Allergies to fish and/or shellfish</u></p><p>Vascepa contains icosapent ethyl, an ethyl ester of the omega-3 fatty acid, eicosapentaenoic acid (EPA), obtained from the oil of fish. It is not known whether patients with allergies to fish and/or shellfish are at increased risk of an allergic reaction to icosapent ethyl. Vascepa should be used with caution in patients with known hypersensitivity to fish and/or shellfish.</p><p>&nbsp;</p><p><u>Hepatic impairment</u></p><p>In patients with hepatic impairment, periodically monitor alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels according to standard medical practice during therapy with Vascepa.</p><p>&nbsp;</p><p><u>Atrial fibrillation or flutter</u></p><p>Icosapent ethyl &nbsp;was associated with an increased risk of atrial fibrillation or flutter requiring hospitalisation in a double-blind placebo-controlled trial. The incidence of atrial fibrillation was greater in patients with a previous history of atrial fibrillation or flutter . Patients, particularly those</p><p>with a relevant medical history, should be monitored for clinical evidence of atrial fibrillation or atrial flutter (e.g., dyspnoea, palpitations, syncope/dizziness, chest discomfort, change in blood pressure, or irregular pulse). Electrocardiographic evaluation should be performed when clinically indicated.</p><p>&nbsp;</p><p><u>Bleeding</u></p><p>Treatment with Vascepa has been associated with an increased incidence of bleeding. Patients taking Vascepa along with antithrombotic agents, i.e., antiplatelet agents, including acetylsalicylic acid, and/or anticoagulants, may be at increased risk of bleeding and should be monitored periodically (see section 4.8).</p><p>&nbsp;</p><p><u>Excipients content</u></p><p>Each capsule contains up to 83&nbsp;mg of sorbitol liquid, non-crystallising, and up to 30&nbsp;mg of maltitol liquid. Vascepa should be used with caution in patients with rare hereditary problems of fructose intolerance.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Icosapent ethyl was studied at the 4&nbsp;g/day dose level with the following medicinal products which are typical substrates of cytochrome P450 enzymes, and no interactions were observed:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp; <em>Omeprazole:</em> In a drug-drug interaction study with 28 healthy adult subjects, icosapent ethyl 4&nbsp;g/day at steady-state did not significantly change the steady-state AUC<sub>&tau;</sub> or C<sub>max</sub> of omeprazole when co-administered at 40&nbsp;mg/day to steady-state.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp; <em>Rosiglitazone:</em> In a drug-drug interaction study with 28 healthy adult subjects, icosapent ethyl 4&nbsp;g/day at steady-state did not significantly change the single dose AUC or C<sub>max</sub> of rosiglitazone at 8&nbsp;mg.</p><p><em>&nbsp;</em></p><p>&middot;&nbsp;&nbsp; <em>Warfarin: </em>In a drug-drug interaction study with 25 healthy adult subjects, icosapent ethyl 4&nbsp;g/day at steady-state did not significantly change the single dose AUC or C<sub>max</sub> of R- and S- warfarin or the anticoagulation pharmacodynamics of warfarin when co-administered as racemic warfarin at 25&nbsp;mg.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp; <em>Atorvastatin: </em>In a drug-drug interaction study of 26 healthy adult subjects, icosapent ethyl 4&nbsp;g/day at steady-state did not significantly change the steady-state AUC<sub>&tau;</sub> or C<sub>max</sub> of atorvastatin, 2-hydroxyatorvastatin, or 4-hydroxyatorvastatin when co-administered with atorvastatin 80&nbsp;mg/day to steady-state.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p><u>Pregnancy</u></p><p>There are a limited amount of data from the use of icosapent ethyl in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3). As a precautionary measure, it is preferable to avoid the use of Vascepa during pregnancy unless the benefit of use outweighs the potential risk to the foetus.</p><p>&nbsp;</p><p><u>Breastfeeding</u></p><p>It is not known whether icosapent ethyl is excreted in human milk. Studies from the literature have shown that the active metabolite EPA is excreted in human milk at levels which correlated to maternal diet. Available toxicological data in rats have shown excretion of icosapent ethyl in milk (see section&nbsp;5.3).</p><p>&nbsp;</p><p>A risk to the suckling child cannot be excluded.</p><p>&nbsp;</p><p>A decision must be made whether to discontinue breastfeeding or to discontinue/abstain from Vascepa therapy considering the benefit of breastfeeding for the child and the benefit of therapy for the woman.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>There are no data on fertility in humans from the use of icosapent ethyl. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>On the basis of its pharmacodynamic profile and clinical trial adverse event data, Vascepa is expected to have no or negligible influence on the ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of </u><u>the safety profile</u></p><p>Adverse reactions below were identified from three well-controlled clinical studies with Vascepa: the MARINE, ANCHOR, and REDUCE-IT studies.&nbsp; MARINE was a 12-week lipid study in patients with severe hypertriglyceridemia, with or without background statin therapy.&nbsp; ANCHOR was a 12-week lipid study in patients with hypertriglyceridemia in which all patients received background statin therapy.&nbsp; REDUCE-IT was a long-term cardiovascular outcomes trial with a median follow-up duration of 4.9&nbsp;years in patients at high risk for cardiovascular disease. All patients in the REDUCE-IT were receiving statin therapy in addition to other cardiovascular medicinal products including antiplatelet agents (79.4%), beta blockers (70.7%), antihypertensives (95.2%), angiotensin converting enzyme (ACE) inhibitors (51.9%), or angiotensin receptor blockers (ARB; 26.9%); 77.5% were taking an ACE inhibitor or ARB. Placebo rates for identified adverse reactions were high and generally similar to treatment with Vascepa.</p><p>&nbsp;</p><p>A very common adverse reaction of bleeding (11.8%) is associated with icosapent ethyl (see section&nbsp;4.4). Common adverse reactions are peripheral oedema (7.8%), constipation (5.4%), atrial fibrillation (5.8%), musculoskeletal pain (4.3%), gout (4.3%), rash (3.0%), arthralgia (2.3%), oropharyngeal pain (1.1%), and eructation (1.1%). Uncommon adverse reactions include hypersensitivity (0.4%) and dysgeusia (0.3%).</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p>Adverse reactions are classified according to frequency and system organ class. Frequency categories are defined according to the following conventions: very common (&ge;1/10), common (&ge;1/100 to &lt;1/10), uncommon (&ge;1/1,000 to 1&lt;100), rare (&ge;1/10,000 to 1&lt;1,000) and very rare (&lt;1/10,000).</p><p>&nbsp;</p><p>Table 1 lists adverse reactions identified in clinical study REDUCE-IT.</p><p>&nbsp;</p><p>Table <!--[if supportFields]><span
style='mso-bookmark:_Hlk41408027'></span><span style='mso-element:field-begin'></span><span
style='mso-bookmark:_Hlk41408027'><span lang=EN-GB style='font-size:11.0pt'><span
style='mso-spacerun:yes'> </span>SEQ Table \* ARABIC <span style='mso-element:
field-separator'></span></span></span><![endif]-->1<!--[if supportFields]><span style='mso-bookmark:
_Hlk41408027'></span><span style='mso-element:field-end'></span><![endif]--> Adverse Reactions</p><table border="1" cellspacing="0" cellpadding="0" style="width:619px"><tbody><tr><td style="vertical-align:top"><p><strong>MedDRA Sytem organ class</strong></p></td><td style="vertical-align:top"><p><strong>Adverse reaction</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>Hypersensitivity<sup>1</sup></p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Pharyngeal swelling</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p>Gout<sup>2</sup></p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Dysgeusia<sup>3</sup></p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>Atrial fibrillation<sup>4,5</sup></p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>Bleeding<sup>6</sup></p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>Arthralgia</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Oropharyngeal pain</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Constipation</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Eructation</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Rash<sup>7</sup></p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>Musculoskeletal pain</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Peripheral oedema<sup>8</sup></p></td><td style="vertical-align:top"><p>Common</p></td></tr></tbody></table><p>1 Includes the synonym Preferred term: Drug sensitivity</p><p>2 Includes the synonym Preferred terms: Gouty tophus and gouty arthritis</p><p>3 Dysguesia describes the &ldquo;verbatim&rdquo; term: Fishy taste</p><p>4 Includes the synonym Preferred term: Atrial flutter</p><p>5 See section Description of selected adverse reactions</p><p>6 See section Description of selected adverse reactions</p><p>7 Includes the synonym Preferred term: Rash generalised</p><p>8 Includes the synonym Preferred term: Peripheral swelling</p><p>&nbsp;</p><p><u>Description of selected adverse reactions</u></p><p>Bleeding at 11.8% was identified as very common in a placebo-controlled cardiovascular outcomes trial for patients receiving icosapent ethyl but was observed similarly in patients receiving placebo at 9.9%. Serious bleeding events were less common at 3% for icosapent ethyl and 2% for placebo. Bleeding includes Preferred terms in the following Standardised MedDRA Queries (SMQs): Gastrointestinal haemorrhage SMQ, Central Nervous System haemorrhages and cerebrovascular conditions SMQ, Haemorrhage terms (excluding laboratory terms) SMQ.</p><p>&nbsp;</p><p>Atrial fibrillation or atrial flutter at 5.8% was identified as common in a placebo-controlled cardiovascular outcomes trial for patients receiving icospanet ethyl but was observed similarly in patients receiving placebo at 4.5%. Adjudicated atrial fibrillation or atrial flutter requiring hospitalisation for 24 or more hours occurred in 3% patients treated with icosapent ethyl compared to 2% patients receiving placebo. The incidence of atrial fibrillation was greater in patients with a previous history of atrial fibrillation or atrial flutter.</p><p>&nbsp;</p><p>The following adverse reactions have been identified from global post-marketing use of Vascepa. Because these reactions are reported voluntarily from a population of uncertain size, it is generally not possible to reliably estimate their frequency or establish causal relationship to drug exposure: blood triglycerides increased, diarrhoea, abdominal discomfort, and pain in the extremities.</p><p>&nbsp;</p><p>-<em> </em>Please report adverse drug events to:</p><p>&nbsp;</p><p><em>Saudi Arabia:</em></p><p>The National Pharmacovigilance Centre (NPC)</p><p>&bull; SFDA Call Center: 19999</p><p>&bull; E-mail: npc.drug@sfda.gov.sa</p><p>&bull; Website: https://ade.sfda.gov.sa</p><p>&nbsp;</p><p><em>United Arab Emirates:</em></p><p>Pharmacovigilance and Medical device section</p><p>Drug Department</p><p>Ministry of Health and Prevention</p><p>P.O. Box: 1853 Dubai</p><p>United Arab Emirates</p><p>&bull; Hotline: 80011111</p><p>&bull; Email: pv@mohap.gov.ae</p><p><em>&nbsp;</em></p><p><em>Oman:</em></p><p>Department of Pharmacovigilance &amp; Drug Information</p><p>Directorate General of Pharmaceutical Affairs &amp; Drug Control</p><p>Ministry of Health, Sultanate of Oman</p><p>Tel: +968 22357687 / +968 22357686</p><p>Fax: +968 22358489</p><p>Email: pharma-vigil@moh.gov.om</p><p>Website: www.moh.gov.om</p><p><em>&nbsp;</em></p><p><em>Kuwait:</em></p><p>Drug &amp; Food Control, Ministry of Health, Kuwait</p><p>Tel.: +965-24811532</p><p>Fax: +965-24811507</p><p>E-mail: Adr_reporting@moh.gov.kw</p><p><em>&nbsp;</em></p><p><em>Other GCC States:</em></p><p>Please contact the relevant competent authority.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no specific treatment for Vascepa overdose. In the event of an overdose, the patient should be treated symptomatically, and supportive measures instituted as required.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Other lipid modifying agents, ATC code: C10AX06</p><p><u>&nbsp;</u></p><p><u>Mechanism of action</u></p><p>Icosapent ethyl is an ethyl ester of the omega-3 fatty acid, eicosapentaenoic acid (EPA). The mechanisms of action contributing to reduction of cardiovascular events with Vascepa are not completely understood. The mechanisms are likely multi-factorial including improved lipoprotein profile with reduction of triglyceride-rich lipoproteins, anti-inflammatory, antioxidant, and membrane stabilising effects, reduction of macrophage accumulation, improved endothelial function, increased fibrous cap thickness/stability, and antiplatelet effects. Each of these mechanisms can beneficially alter the development, progression, and stabilisation of atherosclerotic plaque, as well as the implications of plaque rupture, and preclinical and clinical studies support such benefits with EPA. Systemic and localised anti-inflammatory effects of EPA may result from displacement of pro-inflammatory arachidonic acid (AA), directing catabolism away from eicosanoids (2-series prostaglandins and thromboxanes, and 4-series leukotrienes) to non- or anti-inflammatory mediators. However, the direct clinical meaning of individual findings is not clear.</p><p>&nbsp;</p><p>Studies suggest that EPA reduces hepatic very low-density lipoprotein triglycerides (VLDL-TG) synthesis and/or secretion and enhances TG clearance from circulating VLDL particles.&nbsp; Potential mechanisms of action include increased &beta;-oxidation; inhibition of acyl‑CoA:1,2-diacylglycerol acyltransferase (DGAT); decreased lipogenesis in the liver; and increased plasma lipoprotein lipase activity.</p><p>&nbsp;</p><p><u>Pharmacodynamics</u></p><p>Vascepa improves the lipoprotein profile by suppressing cholesterol-, fatty acid- and triglyceride (TG)-synthesising enzymes, increasing fatty acid &beta;-oxidation, and reducing microsomal triglyceride transfer (MTP) protein, resulting in decreased hepatic TG and very low-density lipoprotein (VLDL) synthesis and release. Vascepa also increases expression of lipoprotein lipase leading to increased TG removal from circulating VLDL and chylomicron particles. In patients with elevated TG levels, Vascepa lowers TG, VLDL, remnant lipoprotein cholesterol, and levels of inflammatory markers such as C-reactive protein. However, TG reduction appears to provide only a minor contribution to the reduction in risk of cardiovascular events with Vascepa.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p><em>Prevention of Cardiovascular Events</em></p><p>REDUCE-IT was a multinational, double-blind, randomised, placebo-controlled, event-driven trial in 8,179&nbsp;(4,089&nbsp;Vascepa, 4,090&nbsp;placebo) statin-treated adult patients enrolled with low-density lipoprotein cholesterol (LDL-C) &gt;1.03&nbsp;mmol/L (40&nbsp;mg/dL) and &le;2.59&nbsp;mmol/L (100&nbsp;mg/dL) and moderately elevated triglyceride (TG) levels (&ge;1.53&nbsp;mmol/L and &lt;5.64&nbsp;mmol/L [&ge;135&nbsp;mg/dL and &lt;500&nbsp;mg/dL] as measured during patient screening, i.e. qualifying visits pre-enrolment) and either established cardiovascular disease (70.7%) or diabetes and other risk factors for cardiovascular disease (29.3%). Patients with established cardiovascular disease were defined as being at least 45&nbsp;years of age and having a documented history of coronary artery disease, cerebrovascular or carotid disease, or peripheral artery disease. Patients with other risk factors for cardiovascular disease were defined as being at least 50&nbsp;years of age with diabetes requiring medical treatment and at least one additional risk factor (including risk factors such as hypertension and low high-density lipoprotein cholesterol levels). Patients were randomly assigned 1:1 to receive either Vascepa (4&nbsp;grams daily) or placebo. The median follow-up duration was 4.9&nbsp;years. Overall, 99.8% of patients were followed for vital status until the end of the trial or death.</p><p>&nbsp;</p><p>The baseline characteristics were balanced between the groups, median age at baseline was 64&nbsp;years (range: 44&nbsp;years to 92&nbsp;years), with 46% being at least 65&nbsp;years old; 28.8% were women. The trial population was 90.2% White, 5.5% Asian, 4.2% identified as Hispanic ethnicity, and 1.9% were Black. Regarding prior diagnoses of cardiovascular disease, 46.7% had prior myocardial infarction, 9.2% had symptomatic peripheral arterial disease, and 6.1% prior unknown stroke or transient ischemic attack (TIA). Selected additional baseline risk factors included hypertension (86.6%), diabetes mellitus (0.7% type 1; 57.8% type 2), eGFR &lt;60&nbsp;mL/min per 1.73&nbsp;m<sup>2</sup> (22.2%), congestive heart failure (17.7%), and current daily cigarette smoking (15.2%). Most patients were taking moderate-intensity (63%) or high-intensity (31%) statin therapy at baseline. Most patients at baseline were taking at least one other cardiovascular medicinal product including antiplatelet agents (79.4%), beta blockers (70.7%), antihypertensives (95.2%), angiotensin converting enzyme (ACE) inhibitors (51.9%), or angiotensin receptor blockers (ARB; 26.9%); 77.5% were taking an ACE inhibitor or ARB. On stable background lipid-lowering therapy, the median [Q1, Q3] LDL-C at baseline was 1.9&nbsp;[1.6, 2.3]&nbsp;mmol/L (75.0&nbsp;[62.0, 89.0]&nbsp;mg/dL); the mean (SD) was 2.0&nbsp;(0.5)&nbsp;mmol/L (76.2&nbsp;[20.3]&nbsp;mg/dL). On stable background lipid-lowering therapy, the median [Q1, Q3] fasting TG was 2.4&nbsp;[2.0, 3.1]&nbsp;mmol/L (216.0&nbsp;[176.0, 272.5]&nbsp;mg/dL); the mean (SD) was 2.6&nbsp;(0.9)&nbsp;mmol/L (233.2&nbsp;[80.1]&nbsp;mg/dL).</p><p>&nbsp;</p><p>Vascepa significantly reduced the risk for the primary composite endpoint (time to first occurrence of cardiovascular death, myocardial infarction, stroke, coronary revascularisation, or hospitalisation for unstable angina; p&lt;0.0001) and the key secondary composite endpoint (time to first occurrence of cardiovascular death, myocardial infarction, or stroke; p&lt;0.0001). The results of the primary and secondary efficacy endpoints are shown in Table&nbsp;2. The Kaplan-Meier estimates of the cumulative incidence of the primary composite endpoint over time are shown in Figure&nbsp;1. Additionally, the Kaplan-Meier estimates of the cumulative incidence of the key secondary composite endpoint over time are shown in Figure&nbsp;2.</p><p>&nbsp;</p><p><strong>Table 2. Effect of VASCEPA on Time to First Occurrence of Cardiovascular Events in Patients with Elevated Triglyceride Levels and Other Risk Factors for Cardiovascular Disease in REDUCE-IT </strong></p><table border="1" cellspacing="0" cellpadding="0"><thead><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2"><p><strong>VASCEPA</strong></p></td><td colspan="2"><p><strong>Placebo</strong></p></td><td><p><strong>VASCEPA<br />vs Placebo</strong></p></td></tr><tr><td><p><strong>N = 4089</strong></p><p><strong>n (%)</strong></p></td><td><p><strong>Incidence Rate<br />(per 100 patient years)</strong></p></td><td><p><strong>N = 4090</strong></p><p><strong>n (%)</strong></p></td><td><p><strong>Incidence Rate<br />(per 100 patient years)</strong></p></td><td><p><strong>Hazard Ratio (95% CI)</strong></p></td></tr></thead><tbody><tr><td colspan="6" style="vertical-align:top"><p><strong>Primary composite endpoint</strong></p></td></tr><tr><td style="vertical-align:top"><p>Cardiovascular death, myocardial infarction, stroke, coronary revascularization, hospitalization for unstable angina (5-point MACE)</p></td><td><p>705</p><p>(17.2)</p></td><td><p>4.3</p></td><td><p>901</p><p>(22.0)</p></td><td><p>5.7</p></td><td><p>0.75</p><p>(0.68, 0.83)</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><strong>Key secondary composite endpoint</strong></p></td></tr><tr><td style="vertical-align:top"><p>Cardiovascular death, myocardial infarction, stroke (3-point MACE)</p></td><td><p>459</p><p>(11.2)</p></td><td><p>2.7</p></td><td><p>606</p><p>(14.8)</p></td><td><p>3.7</p></td><td><p>0.74</p><p>(0.65, 0.83)</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><strong>Other secondary endpoints</strong></p></td></tr><tr><td style="vertical-align:top"><p>Cardiovascular death[1]</p></td><td><p>174</p><p>(4.3)</p></td><td><p>1.0</p></td><td><p>213</p><p>(5.2)</p></td><td><p>1.2</p></td><td><p>0.80</p><p>(0.66, 0.98)</p></td></tr><tr><td style="vertical-align:top"><p>Death by any cause[2]</p></td><td><p>274</p><p>(6.7)</p></td><td><p>1.6</p></td><td><p>310</p><p>(7.6)</p></td><td><p>1.8</p></td><td><p>0.87</p><p>(0.74, 1.02)</p></td></tr><tr><td style="vertical-align:top"><p>Fatal or non-fatal myocardial infarction</p></td><td><p>250</p><p>(6.1)</p></td><td><p>1.5</p></td><td><p>355</p><p>(8.7)</p></td><td><p>2.1</p></td><td><p>0.69</p><p>(0.59, 0.81)</p></td></tr><tr><td style="vertical-align:top"><p>Fatal or non-fatal stroke</p></td><td><p>98</p><p>(2.4)</p></td><td><p>0.6</p></td><td><p>134</p><p>(3.3)</p></td><td><p>0.8</p></td><td><p>0.72</p><p>(0.55, 0.93)</p></td></tr><tr><td style="vertical-align:top"><p>Emergent or urgent coronary revascularisation</p></td><td><p>216</p><p>(5.3)</p></td><td><p>1.3</p></td><td><p>321</p><p>(7.8)</p></td><td><p>1.9</p></td><td><p>0.65</p><p>(0.55, 0.78)</p></td></tr><tr><td style="vertical-align:top"><p>Coronary revascularisation[3]</p></td><td><p>376</p><p>(9.2)</p></td><td><p>2.3</p></td><td><p>544</p><p>(13.3)</p></td><td><p>3.4</p></td><td><p>0.66</p><p>(0.58, 0.76)</p></td></tr><tr><td style="vertical-align:top"><p>Hospitalisation for unstable angina[4]</p></td><td><p>108</p><p>(2.6)</p></td><td><p>0.6</p></td><td><p>157</p><p>(3.8)</p></td><td><p>0.9</p></td><td><p>0.68</p><p>(0.53, 0.87)</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p>[1] Cardiovascular death includes adjudicated cardiovascular deaths and deaths of undetermined causality.</p><p>[2] Death by any cause, or total mortality, is not a component of either the primary composite endpoint or key secondary composite endpoint.</p><p>[3] The predefined composite secondary endpoint included emergent or urgent revascularisation (p&lt;0.0001); coronary revascularisations is the composite of all revascularisation and was predefined as a tertiary endpoint.</p><p>[4] Determined to be caused by myocardial ischemia by invasive/non-invasive testing and requiring emergent hospitalisation.</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p><strong>Figure </strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:11.0pt;
color:black;mso-ansi-language:EN-US;mso-bidi-font-style:italic'><span
style='mso-element:field-begin'></span><span
style='mso-spacerun:yes'> </span>SEQ Figure \* ARABIC <span style='mso-element:
field-separator'></span></span></b><![endif]--><strong>1</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:11.0pt;
color:black;mso-ansi-language:EN-US;mso-bidi-font-style:italic'><span
style='mso-element:field-end'></span></span></b><![endif]--><strong>. Kaplan-Meier Estimated Cumulative Incidence of Primary Composite Endpoint in REDUCE-IT</strong></p><p><!--[if gte vml 1]><v:shapetype id="_x0000_t75" coordsize="21600,21600"
 o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe" filled="f"
 stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="_x0000_i1026" type="#_x0000_t75" style='width:408pt;
 height:269.4pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/ABEERS~1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
</v:shape><![endif]--><img width="544" height="359" src="file:///C:/Users/ABEERS~1/AppData/Local/Temp/msohtmlclip1/01/clip_image002.jpg" /></p><p>Key primary composite endpoint consisted of cardiovascular death, myocardial infarction, stroke, coronary revascularisation, or hospitalisation for unstable angina (5-point MACE)</p><p>CI=confidence interval; RRR = relative risk reduction; ARR= absolute risk reduction; NNT= number needed to treat</p><p>Figure 2.&nbsp; Kaplan-Meier Estimated Incidence of Key Secondary Composite Endpoint in</p><p>REDUCE-IT</p><p><!--[if gte vml 1]><v:shape id="Picture_x0020_3" o:spid="_x0000_i1025"
 type="#_x0000_t75" style='width:411.6pt;height:267.6pt;visibility:visible;
 mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/ABEERS~1/AppData/Local/Temp/msohtmlclip1/01/clip_image003.png"
  o:title=""/>
</v:shape><![endif]--><img width="549" height="357" src="file:///C:/Users/ABEERS~1/AppData/Local/Temp/msohtmlclip1/01/clip_image004.jpg" /></p><p>&nbsp;</p><p>Key secondary composite endpoint consisted of cardiovascular death, myocardial infarction, or stroke (3-point MACE)</p><p>Abbreviations: CI confidence interval; RRR relative risk reduction; ARR absolute risk reduction; NNT number needed to treat</p><p>&nbsp;</p><p>Vascepa significantly reduced the risks for total (first and subsequent) 5-point MACE events by 30% and 3-point MACE events by 28%. It is estimated that for every 1,000&nbsp;patients with high risk of cardiovascular events treated with Vascepa for 5&nbsp;years the following numbers of 5-point MACE could be prevented: 12&nbsp;cardiovascular deaths, 42&nbsp;myocardial infarctions, 14&nbsp;strokes, 76&nbsp;coronary revascularisations, and 16&nbsp;episodes of hospitalisation for unstable angina.</p><p>&nbsp;</p><p>The median TG and LDL-C baseline values were similar between the Vascepa group and placebo group. The median change in TG from baseline to Year&nbsp;1 was -0.4&nbsp;mmol/L (-39&nbsp;mg/dL, -18%) in the Vascepa group and 0.1&nbsp;mmol/L (5&nbsp;mg/dL, 2%) in the placebo group. The median change in LDL-C from baseline to Year&nbsp;1 was 0.1&nbsp;mmol/L (2&nbsp;mg/dL, 3%) in the Vascepa group and 0.2&nbsp;mmol/L (7&nbsp;mg/dL, 10%) in the placebo group. Prespecified analyses of the effect of Vascepa on cardiovascular outcomes in the REDUCE-IT trial showed little to no correlation between either TG or LDL-C response and cardiovascular effect based on baseline or on-study achieved TG or LDL-C levels. See section 5.1 mechanism of action for more information.</p><p>&nbsp;</p><p><em>Severe Hypertriglyceridemia</em></p><p>The effects of Vascepa 4 grams per day were assessed in a randomized, placebo-controlled, double-blind, parallel-group study of adult patients (76 on Vascepa, 75 on placebo) with severe hypertriglyceridemia. Patients whose baseline TG levels were between 500 and 2,000 mg/dL were enrolled in this study for 12 weeks. The median baseline TG and LDL-C levels in these patients were 684 mg/dL and 86 mg/dL, respectively.&nbsp; Median baseline HDL-C level was 27&nbsp;mg/dL. The randomized population in this study was mostly Caucasian (88%) and male (76%). The mean age was 53 years and the mean body mass index was 31 kg/m<sup>2</sup>.&nbsp; Twenty-five percent of patients were on concomitant statin therapy, 28% were diabetics, and 39% of the patients had TG levels &gt;750 mg/dL.</p><p>&nbsp;</p><p>The changes in the major lipoprotein lipid parameters for the groups receiving Vascepa or placebo are shown in Table 2.&nbsp;</p><p>&nbsp;</p><p><strong>Table 2. Median Baseline and Percent Change from Baseline in Lipid Parameters in Patients with Severe Hypertriglyceridemia (&ge;500 mg/dL) </strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:bottom"><p><strong>Parameter</strong></p></td><td colspan="2" style="vertical-align:bottom"><p><strong>Vascepa 4 g/day<br />N=76</strong></p></td><td colspan="2" style="vertical-align:bottom"><p><strong>Placebo<br />N=75</strong></p></td><td rowspan="2" style="vertical-align:bottom"><p><strong>Difference (95% Confidence Interval)</strong></p></td></tr><tr><td style="vertical-align:bottom"><p><strong>Baseline</strong></p></td><td style="vertical-align:bottom"><p><strong>% Change</strong></p></td><td style="vertical-align:bottom"><p><strong>Baseline</strong></p></td><td style="vertical-align:bottom"><p><strong>% Change</strong></p></td></tr><tr><td style="vertical-align:top"><p>TG (mg/dL)</p></td><td style="vertical-align:top"><p>680</p></td><td style="vertical-align:top"><p>-27</p></td><td style="vertical-align:top"><p>703</p></td><td style="vertical-align:top"><p>+10</p></td><td style="vertical-align:top"><p>&nbsp; -33<sup>*</sup> (-47, -22)</p></td></tr><tr><td style="vertical-align:top"><p>LDL-C (mg/dL)</p></td><td style="vertical-align:top"><p>91</p></td><td style="vertical-align:top"><p>-5</p></td><td style="vertical-align:top"><p>86</p></td><td style="vertical-align:top"><p>-3</p></td><td style="vertical-align:top"><p>-2 (-13, +8)</p></td></tr><tr><td style="vertical-align:top"><p>Non-HDL-C (mg/dL)</p></td><td style="vertical-align:top"><p>225</p></td><td style="vertical-align:top"><p>-8</p></td><td style="vertical-align:top"><p>229</p></td><td style="vertical-align:top"><p>+8</p></td><td style="vertical-align:top"><p>-18 (-25, -11)</p></td></tr><tr><td style="vertical-align:top"><p>TC (mg/dL)</p></td><td style="vertical-align:top"><p>254</p></td><td style="vertical-align:top"><p>-7</p></td><td style="vertical-align:top"><p>256</p></td><td style="vertical-align:top"><p>+8</p></td><td style="vertical-align:top"><p>-16 (-22, -11)</p></td></tr><tr><td style="vertical-align:top"><p>HDL-C (mg/dL)</p></td><td style="vertical-align:top"><p>27</p></td><td style="vertical-align:top"><p>-4</p></td><td style="vertical-align:top"><p>27</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>-4 (-9, +2)</p></td></tr><tr><td style="vertical-align:top"><p>VLDL-C (mg/dL)</p></td><td style="vertical-align:top"><p>123</p></td><td style="vertical-align:top"><p>-20</p></td><td style="vertical-align:top"><p>124</p></td><td style="vertical-align:top"><p>+14</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; -29<sup>**</sup> (-43, -14)</p></td></tr><tr><td><p>Apo B (mg/dL)</p></td><td><p>121</p></td><td><p>-4</p></td><td><p>118</p></td><td><p>+4</p></td><td><p>-9<sup>**</sup>(-14, -3)</p></td></tr></tbody></table><p>% Change= Median Percent Change from Baseline</p><p>Difference= Median of [Vascepa % Change &ndash; Placebo % Change] (Hodges-Lehmann Estimate)</p><p>p-values from Wilcoxon rank-sum test</p><p><sup>*</sup>p-value &lt; 0.001 (primary efficacy endpoint)</p><p><sup>**</sup>p-value &lt; 0.05 (key secondary efficacy endpoints determined to be statistically significant according to the pre-specified multiple comparison procedure)</p><p>Vascepa 4 grams per day reduced median TG, VLDL-C, and Apo B levels from baseline relative to placebo.&nbsp; The reduction in TG observed with Vascepa was not associated with elevations in LDL-C levels relative to placebo.</p><p>&nbsp;</p><p>For clinical safety, see Section 4.8</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>The European Medicines Agency has waived the obligation to submit the results of studies with Vascepa in all subsets of the paediatric population for the treatment of hypertriglyceridemia and to reduce the risk cardiovascular events (see section 4.2 for information on paediatric use).</p><p>&nbsp;</p><p>Additionally, the U.S. Food and Drug Administration waived the obligation to submit the results of studies with Vascepa in all subsets of the paediatric population for the treatment of hypertriglyceridemia and to reduce the risk cardiovascular events.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>After oral administration, icosapent ethyl is de-esterified during the absorption process and the active metabolite EPA is absorbed in the small intestine and enters the systemic circulation mainly via the thoracic duct lymphatic system. Peak plasma concentrations of EPA were reached approximately 5&nbsp;hours following oral doses of Vascepa.</p><p>&nbsp;</p><p>Vascepa was administered with or following a meal in all clinical studies; no food effect studies were performed (see section 4.2 for information on dosage and administration).</p><p><u>&nbsp;</u></p><p><u>Distribution</u></p><p>The mean volume of distribution at steady-state of EPA is approximately 88&nbsp;liters. The majority of EPA circulating in plasma is incorporated in phospholipids, triglycerides and cholesteryl esters, and &lt;1% is present as the unesterified fatty acid. Greater than 99% of unesterified EPA is bound to plasma proteins.</p><p><u>&nbsp;</u></p><p><u>Biotransformation and elimination</u></p><p>EPA is mainly metabolised by the liver via beta-oxidation similar to dietary fatty acids. Beta oxidation splits the long carbon chain of EPA into acetyl Coenzyme A, which is converted into energy via the Krebs cycle. Cytochrome P450-mediated metabolism is a minor pathway of elimination of EPA. The total plasma clearance of EPA at steady state is 684&nbsp;mL/hr. The plasma elimination half-life (t<sub>1/2</sub>) of EPA is approximately 89&nbsp;hours. Icosapent ethyl does not undergo renal excretion.</p><p>&nbsp;</p><p><u>&nbsp;</u></p><p><u>Linearity/non-linearity</u></p><p>Oral doses of 2&nbsp;g/day and 4&nbsp;g/day of Vascepa resulted in maximum plasma concentrations of total EPA approximately 5 hours after dosing. The mean terminal half-life of total EPA in plasma was long, ranging between 75 and 89 hours based on baseline-adjusted concentrations (baseline subtracted), and between 113 and 152 hours based on baseline-unadjusted concentrations. Total plasma EPA concentrations returned to baseline by 8 to 13&nbsp;days after the final dose following a 28-day dosing regimen of 2&nbsp;g/day and 4&nbsp;g/day Vascepa. Accumulation of EPA was observed with BID dosing, with quantifiable trough concentrations of total and unesterified EPA in plasma. Steady state was reached by Day 14. Dose-normalized exposures of 2&nbsp;g/day or 4&nbsp;g/day Vascepa were comparable, indicating linear PK in this dose range. Dose-linearity was demonstrated based on comparisons of EPA Cmax and AUC measured via LC/MS-MS assay of EPA concentrations in plasma. Incorporation in RBCs was also evaluated. &nbsp;Within the 28 day dosing period, RBC concentrations of EPA increased in a dose-dependent manner, but had not reached steady-state and consequently linearity across dosages could not be confirmed within that matrix.</p><p>&nbsp;</p><p><u>Pharmacokinetic/pharmacodynamic relationship(s)</u></p><p><em>Triglycerides level/reduction in hypertriglyceridemia</em></p><p>A linear relationship between EPA levels in plasma or red blood cells (RBCs) and TG reduction was observed in two Phase III studies.</p><p><u>&nbsp;</u></p><p><em>Cardiovascular risk reduction</em></p><p>Analyses of the primary (5-point) and key secondary (3-point) MACE endpoints suggest that on-treatment lipoprotein changes had limited influence on cardiovascular risk reductions, while on-treatment steady state serum EPA levels accounted for the majority of the relative risk reduction observed in REDUCE-IT. Baseline serum EPA level was 26&nbsp;&mu;g/mL; compared to patients with an on-treatment steady state serum EPA level below 100&nbsp;&mu;g/mL, patients with on-treatment EPA levels &ge;175&nbsp;&mu;g/mL had a &gt;50% reduced risk of a cardiovascular event.</p><p>&nbsp;</p><p><u>Renal and hepatic impairment</u></p><p>The pharmacokinetics of Vascepa has not been studied in patients with renal or hepatic impairment. Patients did not require routine dose adjustment due to hepatic or renal impairment in a well-controlled cardiovascular outcomes study of Vascepa.</p><p><u>&nbsp;</u></p><p><u>Other special populations</u></p><p>The pharmacokinetics of Vascepa has not been studied in elderly patients. Elderly patients did not require routine dose adjustment in well-controlled clinical studies of Vascepa.</p><p><u>&nbsp;</u></p><p>The pharmacokinetics of Vascepa has not been studied in paediatric subjects.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction and development.</p><p>&nbsp;</p><p><u>Carcinogenesis, Mutagenesis, Impairment of Fertility</u></p><p>In a 2-year rat carcinogenicity study with oral gavage doses of 0.09, 0.27, and 0.91 g/kg/day icosapent ethyl, respectively, males did not exhibit drug-related neoplasms.&nbsp; Hemangiomas and hemangiosarcomas of the mesenteric lymph node, the site of drug absorption, were observed in females at clinically relevant exposures based on body surface area comparisons across species relative to the maximum clinical dose of 4 g/day.&nbsp; Overall incidence of hemangiomas and hemangiosarcomas in all vascular tissues did not increase with treatment.</p><p>&nbsp;</p><p>In a 6-month carcinogenicity study in Tg.rasH2 transgenic mice with oral gavage doses of 0.5, 1, 2, and 4.6 g/kg/day icosapent ethyl, drug-related incidences of benign squamous cell papilloma in the skin and subcutis of the tail was observed in high dose male mice.&nbsp; The papillomas were considered to develop secondary to chronic irritation of the proximal tail associated with fecal excretion of oil and therefore not clinically relevant.&nbsp; Drug-related neoplasms were not observed in female mice.</p><p>&nbsp;</p><p>Icosapent ethyl was not mutagenic with or without metabolic activation in the bacterial mutagenesis (Ames) assay or in the in vivo mouse micronucleus assay.&nbsp; A chromosomal aberration assay in Chinese Hamster Ovary (CHO) cells was positive for clastogenicity with and without metabolic activation.</p><p>&nbsp;</p><p>In pregnant rats given oral gavage doses of 0.3, 1 and 2 g/kg/day icosapent ethyl from gestation through organogenesis all drug treated groups had visceral or skeletal abnormalities including: 13th reduced ribs, additional liver lobes, testes medially displaced and/or not descended at human systemic exposures following a maximum oral dose of 4 g/day based on body surface comparisons.&nbsp; Variations including incomplete or abnormal ossification of various skeletal bones were observed in the 2 g/kg/day group at 5 times human systemic exposure following an oral dose of 4 g/day based on body surface area comparison.<br />&nbsp;</p><p>In a multigenerational developmental study in pregnant rats given oral gavage doses of 0.3, 1, 3 g/kg/day ethyl-EPA from gestation day 7-17, an increased incidence of absent optic nerves and unilateral testes atrophy were observed at &ge;0.3 g/kg/day at human systemic exposure following an oral dose of 4 g/day based on body surface area comparisons across species.&nbsp; Additional variations consisting of early incisor eruption and increased percent cervical ribs were observed at the same exposures.&nbsp; Pups from high dose treated dams exhibited decreased copulation rates, delayed estrus, decreased implantations and decreased surviving fetuses (F2) suggesting multigenerational effects of ethyl-EPA at 7 times human systemic exposure following 4 g/day dose based on body surface area comparisons across species.<br />&nbsp;</p><p>In pregnant rabbits given oral gavage doses of 0.1, 0.3, and 1 g/kg/day from gestation through organogenesis there were increased dead fetuses at 1 g/kg/day secondary to maternal toxicity (significantly decreased food consumption and body weight loss).<br />&nbsp;</p><p>In pregnant rats given ethyl-EPA from gestation day 17 through lactation day 20 at 0.3, 1, 3 g/kg/day complete litter loss was observed in 2/23 litters at the low dose and 1/23 mid-dose dams by post-natal day 4 at human exposures based on a maximum dose of 4 g/day comparing body surface areas across species.&nbsp;</p><p>&nbsp;</p><p>An animal study in lactating rats given oral gavage <sup>14</sup>C-ethyl EPA demonstrated that drug levels were 6 to 14 times higher in milk than in plasma.</p><p>&nbsp;</p><p>In an oral gavage rat fertility study, ethyl-EPA, administered at doses of 0.3, 1, and 3&nbsp;g/kg/day to male rats for 9 weeks before mating and to female rats for 14 days before mating through day 7 of gestation, increased anogenital distance in female pups and increased cervical ribs were observed at 3 g/kg/day (7 times human systemic exposure with 4 g/day clinical dose based on a body surface area comparison).</p><p>&nbsp;</p><p><u>Environmental Risk Assessment (ERA)</u></p><p>&nbsp;</p><p>The active moiety for the drug product is icosapent ethyl, which is the ethyl ester of eicosapentaenoic acid (EPA), one of the omega-3 fatty acids present in fish oil.&nbsp; As this is a naturally occurring substance, no extraordinary circumstances exist that may affect the quality of the human environment.&nbsp; Further, medical use of the drug product will not significantly alter the concentration or distribution of the substance, its metabolites, or degradation products in the environment.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Capsule fill</u></p><p>all-rac-alpha-tocopherol</p><p><u>&nbsp;</u></p><p><u>Capsule shell</u></p><p>Gelatin</p><p>Glycerol</p><p>Maltitol liquid (E965&nbsp;ii)</p><p>Sorbitol liquid, non-crystallising (E420&nbsp;ii)</p><p>Purified water</p><p>Lecithin</p><p>&nbsp;</p><p><u>Printing ink</u></p><p>Titanium dioxide</p><p>Propylene glycol</p><p>Hypromellose</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not Applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30<sup>o</sup>C.&nbsp;</p><p>Keep out of reach of children.</p><p>Bottle: keep the bottle tightly closed in order to protect from moisture.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>High density polyethylene (HDPE) bottles with a child-resistant polypropylene heat induction sealed closure containing 120&nbsp;soft capsules.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements for disposal.</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Amarin Pharmaceuticals Ireland Ltd.
C/O Amarin Pharma Inc.
440 Route 22
Bridgewater, NJ 08807, USA
Tel:  +1 908 719 3012

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                June 2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>